


PHARMACEUTICAL 2021

Enliven Therapeutics Inc. Rank 88 of 402





PHARMACEUTICAL 2021



Enliven Therapeutics Inc. Rank 88 of 402

The relative strengths and weaknesses of Enliven Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enliven Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Enliven Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 166% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	90,405
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,247
Liabilities, Non-Current	0
Other Assets	88
Other Compr. Net Income	-28
Other Expenses	0
Other Liabilities	160
Other Net Income	338
Other Revenues	0
Property and Equipment	349
Research and Development	32,154
Selling, General and Administrative Expense	9,544

Output Variable	Value in 1000 USD
Assets	90,842
Liabilities	6,407
Expenses	41,698
Revenues	0
Stockholders Equity	84,435
Net Income	-41,360
Comprehensive Net Income	-41,374
Economic Capital Ratio	214%

